公开(公告)号：US20210228554A1

公开(公告)日：2021-07-29

申请号：US17221555

申请日：2021-04-02

Applicant: Novartis AG

Inventor： Urs BAETTIG ,  Kamlesh Jagdis BALA ,  Emma BUDD ,  Lee EDWARDS ,  Catherine HOWSHAM ,  Glyn Alan HUGHES ,  Darren Mark LE GRAND ,  Katrin SPIEGEL

IPC: A61K31/44 ,  A61K31/4418 ,  C07D213/81 ,  C07D401/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/5377 ,  C07D213/38 ,  C07D401/12 ,  C07D403/12 ,  A61K31/4412 ,  A61K45/06 ,  C07D405/04 ,  C07D241/26

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.